Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli.
Details
Serval ID
serval:BIB_C94989B9E28D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli.
Journal
Antimicrobial agents and chemotherapy
ISSN
1098-6596 (Electronic)
ISSN-L
0066-4804
Publication state
Published
Issued date
18/10/2023
Peer-reviewed
Oui
Volume
67
Number
10
Pages
e0054723
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli, alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant E. coli, including metallo-β-lactamase producers.
Keywords
beta-Lactamase Inhibitors/pharmacology, Escherichia coli, Anti-Bacterial Agents/pharmacology, beta-Lactamases/genetics, Meropenem, Carbapenems/pharmacology, Azabicyclo Compounds/pharmacology, Microbial Sensitivity Tests, avibactam, ceftibuten, faropenem, oral penem, sulopenem, susceptibility testing, taniborbactam, tebipenem, β-lactamase
Pubmed
Web of science
Create date
19/09/2023 11:57
Last modification date
07/11/2023 7:10
Usage data
